Folgen
Frank Dörje Dr. Prof. ; MBA
Frank Dörje Dr. Prof. ; MBA
Pharmacy Department, Erlangen University Hospital, Germany
Bestätigte E-Mail-Adresse bei uk-erlangen.de - Startseite
Titel
Zitiert von
Zitiert von
Jahr
Antagonist binding profiles of five cloned human muscarinic receptor subtypes
F Dörje, J Wess, G Lambrecht, R Tacke, E Mutschler, MR Brann
7761991
In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease
R Atreya, H Neumann, C Neufert, MJ Waldner, U Billmeier, Y Zopf, ...
Nature medicine 20 (3), 313-318, 2014
4082014
The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3
A Seithel, S Eberl, K Singer, D Auge, G Heinkele, NB Wolf, F Dörje, ...
Drug metabolism and disposition 35 (5), 779-786, 2007
2432007
Immunological detection of muscarinic receptor subtype proteins (m1-m5) in rabbit peripheral tissues.
F Dörje, AI Levey, MR Brann
Molecular pharmacology 40 (4), 459-462, 1991
2271991
Delineation of muscarinic receptor domains conferring selectivity of coupling to guanine nucleotide-binding proteins and second messengers.
J Wess, TI Bonner, F Dörje, MR Brann
Molecular pharmacology 38 (4), 517-523, 1990
2151990
Role of P-Glycoprotein Inhibition for Drug Interactions: Evidence from In Vitro and Pharmacoepidemiological Studies
S Eberl, B Renner, A Neubert, M Reisig, I Bachmakov, J König, F Dörje, ...
Clinical pharmacokinetics 46, 1039-1049, 2007
1492007
Development of a lauric acid/albumin hybrid iron oxide nanoparticle system with improved biocompatibility
J Zaloga, C Janko, J Nowak, J Matuszak, S Knaup, D Eberbeck, R Tietze, ...
International journal of nanomedicine, 4847-4866, 2014
1332014
Intensified pharmaceutical care is improving immunosuppressive medication adherence in kidney transplant recipients during the first post-transplant year: a quasi-experimental …
R Joost, F Dörje, J Schwitulla, KU Eckardt, C Hugo
Nephrology Dialysis Transplantation 29 (8), 1597-1607, 2014
982014
Novel pharmacological profile of muscarinic receptors mediating contraction of the guinea-pig uterus
F Dörje, T Friebe, R Tacke, E Mutschler, G Lambrecht
Naunyn-Schmiedeberg's archives of pharmacology 342, 284-289, 1990
751990
Selectivity profile of the novel muscarinic antagonist UH‐AH 37 determined by the use of cloned receptors and isolated tissue preparations
J Wess, G Lambrecht, E Mutschler, MR Brann, F Dörje
British journal of pharmacology 102 (1), 246-250, 1991
641991
Pharmaceutical formulation of HSA hybrid coated iron oxide nanoparticles for magnetic drug targeting
J Zaloga, M Pöttler, G Leitinger, RP Friedrich, G Almer, S Lyer, E Baum, ...
European Journal of Pharmaceutics and Biopharmaceutics 101, 152-162, 2016
582016
The randomized AMBORA trial: Impact of pharmacological/pharmaceutical care on medication safety and patient-reported outcomes during treatment with new oral anticancer agents
P Dürr, K Schlichtig, C Kelz, B Deutsch, R Maas, MJ Eckart, J Wilke, ...
Journal of Clinical Oncology 39 (18), 1983-1994, 2021
532021
New oral anti-cancer drugs and medication safety
K Schlichtig, P Dürr, F Dörje, MF Fromm
Deutsches Ärzteblatt international 116 (46), 775, 2019
492019
Hospital use of systemic antifungal drugs
K de With, M Steib-Bauert, H Knoth, F Dörje, E Strehl, U Rothe, L Maier, ...
BMC clinical pharmacology 5, 1-6, 2005
282005
Clinical pharmacy services in Germany: a national survey
C Schulz, A Fischer, W Vogt, K Leichenberg, U Warnke, A Liekweg, ...
European Journal of Hospital Pharmacy 28 (6), 301-305, 2021
252021
Antibiotic use in German university hospitals 1998–2000 (Project INTERUNI-II)
K de With, J Bergner, R Bühner, F Dörje, C Gonnermann, M Haber, ...
International journal of antimicrobial agents 24 (3), 213-218, 2004
242004
Der bundeseinheitliche Medikationsplan in der Praxis
H Dormann, R Maas, C Eickhoff, U Müller, M Schulz, D Brell, ...
Bundesgesundheitsblatt Gesundh. Gesundh 61, 1093-1102, 2018
23*2018
Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
S Fischer, S Cohnen, E Klenske, H Schmitt, F Vitali, S Hirschmann, ...
Therapeutic advances in gastroenterology 14, 1756284820982802, 2021
182021
Preventive counselling for public health in pharmacies in South Germany
K Schmiedel, H Schlager, F Dörje
International journal of clinical pharmacy 35, 138-144, 2013
182013
Medication errors during treatment with new oral anticancer agents: Consequences for clinical practice based on the AMBORA study
K Schlichtig, P Dürr, F Dörje, MF Fromm
Clinical Pharmacology & Therapeutics 110 (4), 1075-1086, 2021
172021
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20